On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants from underrepresented racial and ethnic populations, specifically Black or African American, Hispanic/Latino, Indigenous and Native American, Asian, Native Hawaiian and Other Pacific Islanders, and other persons of color.
The new FDA guidance adds a lot of work to your already full plate. Let Elligo's experience make creating and implementing your Race and Diversity Plan achievable and uncomplicated.
